肝外胆管癌放疗的研究进展

doi:10.3760/cma.j.cn371439-20200224-00051

摘要/Abstract

摘要：

肝外胆管癌是一种较为罕见的消化系统恶性肿瘤,其复发率高,预后差。随着现代医学和放疗技术的发展,放疗联合手术、化疗、胆道支架等在可切除及不可切除的肝外胆管癌治疗过程中占据越来越重要的地位。目前已有大量研究显示外照射放疗、近距离腔内放疗、立体定向放疗等多种放疗技术具有良好的安全性和疗效,但其临床应用仍存在争议。

关键词: 胆管肿瘤, 放射疗法, 治疗结果

Abstract:

Extrahepatic cholangiocarcinoma is a rare, aggressive malignancy of the digestive system with high recurrence rate and poor prognosis. With the development of modern medicine and radiotherapy technology, combined with surgery, chemotherapy, and biliary stent, etc., radiotherapy plays a more and more important role in the treatment of resectable and unresectable patients. At present, a large number of studies have shown that external beam radiotherapy, intraluminal brachytherapy, stereotactic body radiation therapy and other kinds of radiotherapy techniques have good safety and efficacy, but its clinical application is still controversial.

Key words: Bile duct neoplasms, Radiotherapy, Treatment outcome

周蔚文, 孙晓南. 肝外胆管癌放疗的研究进展[J]. 国际肿瘤学杂志, 2020, 47(7): 431-435.

Zhou Weiwen, Sun Xiaonan. Research progress of radiotherapy in extrahepatic cholangiocarcinoma[J]. Journal of International Oncology, 2020, 47(7): 431-435.

参考文献 38

[1]	Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2016,27(suppl 5):v28-v37. DOI: 10.1093/annonc/mdw324. doi: 10.1093/annonc/mdw324 pmid: 27664259
[2]	Gkika E, Hallauer L, Kirste S, et al. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma[J]. BMC Cancer, 2017,17:781. DOI: 10.1186/s12885-017-3788-1. doi: 10.1186/s12885-017-3788-1 pmid: 29162055
[3]	Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling[J]. Am Soc Clin Oncol Educ Book, 2016,35:e194-e203. DOI: 10.1200/EDBK_160831. doi: 10.1200/EDBK_160831 pmid: 27249723
[4]	Sallinen V, Sirén J, Mäkisalo H, et al. Differences in prognostic factors and recurrence patterns after curative-intent resection of perihilar and distal cholangiocarcinomas[J]. Scand J Surg, 2019: 1457496919832150. DOI: 10.1177/1457496919832150.
[5]	Ghiassi-Nejad Z, Tarchi P, Moshier E, et al. Prognostic factors and patterns of locoregional failure after surgical resection in patients with cholangiocarcinoma without adjuvant radiation therapy: optimal field design for adjuvant radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2017,99(4):805-811. DOI: 10.1016/j.ijrobp.2017.06.2467. doi: 10.1016/j.ijrobp.2017.06.2467 pmid: 29063849
[6]	National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology: Hepatobiliary Cancers (Verion 4.2019)[EB/OL]. [ 2019- 12- 20]. http://www.nccn.org.
[7]	Wellner UF, Shen Y, Keck T, et al. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival[J]. Surg Today, 2017,47(3):271-279. DOI: 10.1007/s00595-016-1362-0. doi: 10.1007/s00595-016-1362-0 pmid: 27236779
[8]	Kim BH, Kim K, Chie EK, et al. Long-term outcome of distal cholangiocarcinoma after pancreaticoduodenectomy followed by adjuvant chemoradiotherapy: a 15-year experience in a single institution[J]. Cancer Res Treat, 2017,49(2):473-483. DOI: 10.4143/crt.2016.166. doi: 10.4143/crt.2016.166 pmid: 27554480
[9]	Ecker BL, Vining CC, Roses RE, et al. Identification of patients for adjuvant therapy after resection of carcinoma of the extrahepatic bile ducts: a propensity score-matched analysis[J]. Ann Surg Oncol, 2017,24(13):3926-3933. DOI: 10.1245/s10434-017-6095-9. pmid: 28952140
[10]	Hester C, Nassour I, Adams-Huet B, et al. Improved survival in surgically resected distal cholangiocarcinoma treated with adjuvant therapy: a propensity score matched analysis[J]. J Gastrointest Surg, 2018,22(12):2080-2087. DOI: 10.1007/s11605-018-3875-x. doi: 10.1007/s11605-018-3875-x pmid: 30030718
[11]	Dover LL, Oster RA, Mcdonald AM, et al. Impact of adjuvant chemoradiation on survival in patients with resectable cholangio-carcinoma[J]. HPB (Oxford), 2016,18(10):843-850. DOI: 10.1016/j.hpb.2016.07.008. doi: 10.1016/j.hpb.2016.07.008
[12]	Kim YS, Hwang IG, Park SE, et al. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma[J]. Cancer Chemother Pharmacol, 2016,77(5):979-985. DOI: 10.1007/s00280-016-3014-x. pmid: 27017615
[13]	Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015,33(24):2617-2622. DOI: 10.1200/JCO.2014.60.2219. doi: 10.1200/JCO.2014.60.2219 pmid: 25964250
[14]	Petrova E, Rückert F, Zach S, et al. Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study[J]. Langenbecks Arch Surg, 2017,402(5):831-840. DOI: 10.1007/s00423-017-1590-9. doi: 10.1007/s00423-017-1590-9 pmid: 28612115
[15]	Jung JH, Lee HJ, Lee HS, et al. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma[J]. World J Gastroenterol, 2017,23(18):3301-3308. DOI: 10.3748/wjg.v23.i18.3301. doi: 10.3748/wjg.v23.i18.3301 pmid: 28566890
[16]	Sumiyoshi T, Shima Y, Okabayashi T, et al. Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma[J]. World J Surg, 2018,42(9):2910-2918. DOI: 10.1007/s00268-018-4558-1. pmid: 29511872
[17]	Zamora-Valdes D, Heimbach JK. Liver transplant for cholangiocarcinoma[J]. Gastroenterol Clin North Am, 2018,47(2):267-280. DOI: 10.1016/j.gtc.2018.01.002. doi: 10.1016/j.gtc.2018.01.002 pmid: 29735023
[18]	Frosio F, Mocchegiani F, Conte G, et al. Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: review of the literature[J]. World J Gastrointest Surg, 2019,11(6):279-286. DOI: 10.4240/wjgs.v11.i6.279. doi: 10.4240/wjgs.v11.i6.279 pmid: 31367275
[19]	Croome KP, Rosen CB, Heimbach JK, et al. Is liver transplantation appropriate for patients with potentially resectable de novo hilar cholangiocarcinoma?[J]. J Am Coll Surg, 2015,221(1):130-139. DOI: 10.1016/j.jamcollsurg.2015.01.064. doi: 10.1016/j.jamcollsurg.2015.01.064 pmid: 25872685
[20]	Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease[J]. Ann Surg, 2018,267(5):797-805. DOI: 10.1097/SLA.0000000000002574. doi: 10.1097/SLA.0000000000002574 pmid: 29064885
[21]	Moris D, Kostakis ID, Machairas N, et al. Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis[J]. PLoS One, 2019,14(7):e0220527. DOI: 10.1371/journal.pone.0220527. doi: 10.1371/journal.pone.0220527 pmid: 31365594
[22]	Mantel HT, Westerkamp AC, Adam R, et al. Strict selection alone of patients undergoing liver transplantation for hilar cholangio-carcinoma is associated with improved survival[J]. PLoS One, 2016,11(6):e0156127. DOI: 10.1371/journal.pone.0156127. doi: 10.1371/journal.pone.0156127 pmid: 27276221
[23]	Assistance Publique. Liver resection versus radio-chemotherapy-transplantation for hilar cholangiocarcinoma (TRANSPHIL)[EB/OL]. [2020-1-20]. https://clinicaltrials.gov/ct2/show/study/NCT02232932.
[24]	Bolm L, Kaesmann L, Bartscht T, et al. Outcomes after radio(chemo)therapy for non-metastatic bile duct cancer[J]. In Vivo, 2017,31(1):117-120. DOI: 10.21873/invivo.11033. pmid: 28064229
[25]	Autorino R, Mattiucci GC, Ardito F, et al. Radiochemotherapy with gemcitabine in unresectable extrahepatic cholangiocarcinoma: long-term results of a phase Ⅱ study[J]. Anticancer Res, 2016,36(2):737-740. pmid: 26851032
[26]	Torgeson A, Lloyd S, Boothe D, et al. Chemoradiation therapy for unresected extrahepatic cholangiocarcinoma: a propensity score-matched analysis[J]. Ann Surg Oncol, 2017,24(13):4001-4008. DOI: 10.1245/s10434-017-6131-9. doi: 10.1245/s10434-017-6131-9 pmid: 29043526
[27]	Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019,20(5):663-673. DOI: 10.1016/S1470-2045(18)30915-X. doi: 10.1016/S1470-2045(18)30915-X pmid: 30922733
[28]	Tao R, Krishnan S, Bhosale PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoper-able intrahepatic cholangiocarcinoma: a retrospective dose response analysis[J]. J Clin Oncol, 2016,34(3):219-226. DOI: 10.1200/JCO.2015.61.3778. doi: 10.1200/JCO.2015.61.3778 pmid: 26503201
[29]	Skowronek J, Zwierzchowski G. Brachytherapy in the treatment of bile duct cancer—a tough challenge[J]. J Contemp Brachytherapy, 2017,9(2):187-195. DOI: 10.5114/jcb.2017.66893. pmid: 28533809
[30]	Tan Y, Zhu JY, Qiu BA, et al. Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma[J]. Oncol Lett, 2015,10(4):2537-2542. DOI: 10.3892/ol.2015.3589. doi: 10.3892/ol.2015.3589 pmid: 26622885
[31]	Xu X, Li J, Wu J, et al. A systematic review and meta-analysis of intraluminal brachytherapy versus stent alone in the treatment of malignant obstructive jaundice[J]. Cardiovasc Intervent Radiol, 2018,41(2):206-217. DOI: 10.1007/s00270-017-1827-6. doi: 10.1007/s00270-017-1827-6 pmid: 29075881
[32]	Nguyen NA, Timotin E, Hunter R, et al. High-dose rate intraluminal brachytherapy: an effective palliation for cholangiocarcinoma causing bile duct obstruction[J]. Surg Oncol, 2018,27(4):625-629. DOI: 10.1016/j.suronc.2018.07.004. doi: 10.1016/j.suronc.2018.07.004 pmid: 30449482
[33]	Feng M, Suresh K, Schipper MJ, et al. Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial[J]. JAMA Oncol, 2018,4(1):40-47. DOI: 10.1001/jamaoncol.2017.2303. doi: 10.1001/jamaoncol.2017.2303 pmid: 28796864
[34]	Venkat PS, Hoffe SE, Frakes JM. Stereotactic body radiation therapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017,24(3):1073274817729259. DOI: 10.1177/1073274817729259. doi: 10.1177/1073274817729259 pmid: 28975831
[35]	Mahadevan A, Dagoglu N, Mancias J, et al. Stereotactic body radiotherapy (SBRT) for intrahepatic and hilar cholangiocarcinoma[J]. J Cancer, 2015,6(11):1099-1104. DOI: 10.7150/jca.13032. pmid: 26516357
[36]	Sandler KA, Veruttipong D, Agopian VG, et al. Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intra-hepatic cholangiocarcinoma[J]. Adv Radiat Oncol, 2016,1(4):237-243. DOI: 10.1016/j.adro.2016.10.008. pmid: 28740893
[37]	Frakulli R, Buwenge M, Macchia G, et al. Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review[J], 2019,92(1097):20180688. DOI: 10.1259/bjr.20180688.
[38]	Brunner TB, Blanck O, Lewitzki V, et al. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma[J]. Radiother Oncol, 2019,132:42-47. DOI: 10.1016/j.radonc.2018.11.015. doi: 10.1016/j.radonc.2018.11.015 pmid: 30825968